Ondrej Fiala1, Milos Pesek2, Jindrich Finek3, Lucie Benesova4, Marek Minarik4, Zbynek Bortlicek5, Ondrej Topolcan6. 1. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic fiala.o@centrum.cz. 2. Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic. 3. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic. 4. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. 5. Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. 6. Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Czech Republic.
Abstract
BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. Copyright
BACKGROUND: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. PATIENTS AND METHODS: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. RESULTS: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). CONCLUSION: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. Copyright
Authors: Álvaro Ruibal; Pablo Aguiar; María Carmen Del Río; Matilde Isabel Nuñez; Virginia Pubul; Michel Herranz Journal: Int J Mol Sci Date: 2015-02-18 Impact factor: 5.923
Authors: Kristine R Jakobsen; Birgitte S Paulsen; Rikke Bæk; Kim Varming; Boe S Sorensen; Malene M Jørgensen Journal: J Extracell Vesicles Date: 2015-03-02